Anti-restenotic Therapies for Peripheral Arterial Disease
Vincent Varghese
Division of Interventional Cardiology and Endovascular Medicine, Deborah Heart and Lung Center, Browns Mills, New Jersey 08015, USA.
Jon C. George *
Division of Interventional Cardiology and Endovascular Medicine, Deborah Heart and Lung Center, Browns Mills, New Jersey 08015, USA.
*Author to whom correspondence should be addressed.
Abstract
Defining the ideal treatment for peripheral arterial disease remains an ongoing endeavor. The initial treatment standard of balloon angioplasty and stenting has produced suboptimal long-term outcomes due to in-stent restenosis and the subsequent need for revascularization. Yet, the field of endovascular medicine has seen an explosion of new technologies, which have yielded promising early and mid-term results. Anti-restenotic drug therapies have the potential to reduce neointimal hyperplasia, in-stent restenosis, and improve vessel patency in femoro-popliteal arteries. We discuss herein current and future drug eluting technologies across various delivery methods and platforms.
Keywords: Peripheral arterial disease, stent, restenosis, anti-restenotic therapy, drug-coated balloon, drug-eluting stent.